Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes.
Journal
Chemical research in toxicology
ISSN: 1520-5010
Titre abrégé: Chem Res Toxicol
Pays: United States
ID NLM: 8807448
Informations de publication
Date de publication:
18 04 2022
18 04 2022
Historique:
pubmed:
22
3
2022
medline:
20
4
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Cytotoxic blistering agents such as sulfur mustard and nitrogen mustard (HN2) were synthesized for chemical warfare. Toxicity is due to reactive chloroethyl side chains that modify and damage cellular macromolecules including DNA and proteins. In response to DNA damage, cells initiate a DNA damage response directed at the recruitment and activation of repair-related proteins. A central mediator of the DNA damage response is p53, a protein that plays a critical role in regulating DNA repair. We found that HN2 causes cytosolic and nuclear accumulation of p53 in HaCaT keratinocytes; HN2 also induced post-translational modifications on p53 including S15 phosphorylation and K382 acetylation, which enhance p53 stability, promote DNA repair, and mediate cellular metabolic responses to stress. HN2 also cross-linked p53, forming dimers and high-molecular-weight protein complexes in the cells. Cross-linked multimers were also modified by K48-linked ubiquitination indicating that they are targets for proteasome degradation. HN2-induced modifications transiently suppressed the transcriptional activity of p53. Using recombinant human p53, HN2 alkylation was found to be concentration- and redox status-dependent. Dithiothreitol-reduced protein was more efficiently cross-linked indicating that p53 cysteine residues play a key role in protein modification. LC-MS/MS analysis revealed that HN2 directly alkylated p53 at C124, C135, C141, C176, C182, C275, C277, H115, H178, K132, and K139, forming both monoadducts and cross-links. The formation of intermolecular complexes was a consequence of HN2 cross-linked cysteine residues between two molecules of p53. Together, these data demonstrate that p53 is a molecular target for mustard vesicants. Modification of p53 likely mediates cellular responses to HN2 including DNA repair and cell survival contributing to vesicant-induced cytotoxicity.
Identifiants
pubmed: 35312310
doi: 10.1021/acs.chemrestox.1c00420
pmc: PMC9491701
mid: NIHMS1833928
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Mechlorethamine
50D9XSG0VR
Cysteine
K848JZ4886
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
636-650Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES005022
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS108956
Pays : United States
Organisme : NIAMS NIH HHS
ID : U54 AR055073
Pays : United States
Références
Protein Sci. 2010 Dec;19(12):2267-78
pubmed: 20878668
Mutat Res. 2014 May-Jun;763-764:53-63
pubmed: 24732344
Int J Mol Sci. 2021 Oct 31;22(21):
pubmed: 34769259
Nat Rev Mol Cell Biol. 2019 Apr;20(4):199-210
pubmed: 30824861
Eur J Med Chem. 2018 May 10;151:401-433
pubmed: 29649739
Biochemistry. 2007 Jul 3;46(26):7765-80
pubmed: 17555331
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5271-80
pubmed: 27551077
Carcinogenesis. 1993 May;14(5):833-9
pubmed: 8504475
Biochem Biophys Res Commun. 2017 Jan 1;482(1):154-158
pubmed: 27833016
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12324-9
pubmed: 17620598
Mol Cell Biol. 2018 Mar 29;38(8):
pubmed: 29378830
Annu Rev Biochem. 2008;77:557-82
pubmed: 18410249
Mol Cell. 2001 Dec;8(6):1243-54
pubmed: 11779500
Nat Rev Mol Cell Biol. 2015 Jul;16(7):393-405
pubmed: 26122615
J Mol Cell Biol. 2019 Jul 19;11(7):564-577
pubmed: 31282934
Chem Res Toxicol. 2014 Jan 21;27(1):61-75
pubmed: 24274902
J Am Soc Mass Spectrom. 2011 May;22(5):888-97
pubmed: 21472523
Toxicol Lett. 2015 Jun 15;235(3):161-71
pubmed: 25891025
Oncogene. 2010 Apr 29;29(17):2560-76
pubmed: 20208557
Oncogene. 1999 Dec 13;18(53):7644-55
pubmed: 10618704
Chem Res Toxicol. 2013 Aug 19;26(8):1263-71
pubmed: 23859065
Mol Cell Biol. 1995 Jul;15(7):3892-903
pubmed: 7791795
Toxicol Lett. 2012 Feb 25;209(1):1-10
pubmed: 22119920
Toxicol Sci. 2010 Mar;114(1):5-19
pubmed: 19833738
Nucleic Acids Res. 2014 Jul;42(12):7666-80
pubmed: 24928858
J Mol Cell Biol. 2019 Apr 1;11(4):330-341
pubmed: 30892598
Chem Res Toxicol. 2019 Jun 17;32(6):1123-1133
pubmed: 30964658
Cell Death Differ. 2018 Jan;25(1):133-143
pubmed: 29125602
Nucleic Acids Res. 2002 Jun 1;30(11):2340-8
pubmed: 12034820
Nat Commun. 2019 Jul 30;10(1):3404
pubmed: 31363125
FEBS Lett. 2014 Aug 19;588(16):2600-9
pubmed: 24747877
Apoptosis. 2006 Sep;11(9):1545-59
pubmed: 16738803
Fundam Clin Pharmacol. 2005 Jun;19(3):297-315
pubmed: 15910653
Cancer Cell. 2009 May 5;15(5):376-88
pubmed: 19411067
Pharmacol Rev. 1996 Jun;48(2):289-326
pubmed: 8804107
Nat Rev Cancer. 2020 Aug;20(8):471-480
pubmed: 32404993
Cell Death Dis. 2018 Apr 18;9(5):439
pubmed: 29670092
Oncogene. 2003 Jan 9;22(1):117-30
pubmed: 12527914
Semin Cancer Biol. 2021 Mar 27;:
pubmed: 33785447
Chem Res Toxicol. 2015 Nov 16;28(11):2091-103
pubmed: 26451472
Cell Death Differ. 2018 Jan;25(1):104-113
pubmed: 29149101
Cancer Gene Ther. 2000 May;7(5):749-56
pubmed: 10830722
Biochemistry. 1995 Jan 31;34(4):1439-45
pubmed: 7827092
Mol Carcinog. 1992;5(2):102-6
pubmed: 1554407
Toxicol Lett. 2020 Jun 15;326:78-82
pubmed: 32173488